Compare AU
Compare DRUG vs. HGEN
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the BetaShares Global Healthcare ETF - Currency Hedged (DRUG) and the Global Hydrogen Companies (HGEN). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
DRUG | HGEN | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 360 |
Median incremental investment | $967.00 | $645.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,905.75 | $637.56 |
Average age group | 26 - 35 | > 35 |
Key Summary
DRUG | HGEN | |
|---|---|---|
Strategy | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. | HGEN.AX was created on 2021-10-06 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 26.31m in AUM and 31 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Global Hydrogen ESG Index. |
Top 3 holdings | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) | Bloom Energy Corp Class A (27.67 %) Plug Power Inc (10.83 %) Doosan Fuel Cell Ordinary Shares (7.44 %) |
Top 3 industries | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) | Industrials (96.09 %) Utilities (7.76 %) Consumer Staples (4.09 %) |
Top 3 countries | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) | United States (39.09 %) Korea (19.33 %) Norway (11.75 %) |
Management fee | 0.57 % | 0.69 % |
Key Summary
DRUG | HGEN | |
|---|---|---|
Issuer | BetaShares | Global X |
Tracking index | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD | Solactive Global Hydrogen Index - Benchmark TR Net |
Asset class | ETF | ETF |
Management fee | 0.57 % | 0.69 % |
Price | $8.15 | $5.04 |
Size | $182.401 million | $28.976 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 1.90 % | 0.16 % |
Market | ASX | ASX |
First listed date | 08/08/2016 | 06/10/2021 |
Purchase fee | $6.50 | $6.50 |
Community Stats
DRUG | HGEN | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 63 | 360 |
Median incremental investment | $967.00 | $645.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,905.75 | $637.56 |
Average age group | 26 - 35 | > 35 |
Pros and Cons
DRUG | HGEN | |
|---|---|---|
Pros |
| |
Cons |
|
DRUG | HGEN |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |